Pharmaceutical Executive
As new ICH GCP draft guidelines now require root cause analysis, novel methods for risk analysis and triage must be adopted in drug development.
Clara Heering
Advertisement
Articles by Clara Heering
Advertisement
Latest Updated Articles
What Errors Do We Miss in Clinical Trials?March 8th 2016
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
2
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
3
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
4
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
5